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Abstract: Although major strides have been made in developing and testing various anti-
acanthamoebic drugs, recurrent infections, inadequate treatment outcomes, health complications, 
and side effects associated with the use of currently available drugs necessitate the development of 
more effective and safe therapeutic regimens. For any new anti-acanthamoebic drugs to be more 
effective, they must have either superior potency and safety or at least comparable potency and an 
improved safety profile compared to the existing drugs. The development of the so-called ‘next-
generation’ anti-acanthamoebic agents to address this challenge is an active area of research. Here, 
we review the current status of anti-acanthamoebic drugs and discuss recent progress in identifying 
novel pharmacological targets and new approaches, such as drug repurposing, development of 
small interfering RNA (siRNA)-based therapies and testing natural products and their derivatives. 
Some of the discussed approaches have the potential to change the therapeutic landscape of 
Acanthamoeba infections. 
Keywords: Acanthamoeba; combination therapy; alternative treatment; drug discovery; natural 
products; drug repurposing 
 
1. Introduction 
The unicellular eukaryotic Acanthamoeba spp. are ubiquitous free-living protists and can survive 
in various environments, such as water, soil and air. During its life cycle (Figure 1), Acanthamoeba can 
undergo a phenotypic transition, under stressful conditions, from being an active trophozoite to a 
dormant cyst and vice versa [1]. The trophozoite is irregular in shape with pseudopods for 
locomotion and spike-like protrusions called acanthopodia [2]. The latter mediate the adhesion of 
Acanthamoeba to biological and inert surfaces [3]. The subcellular features of trophozoite include 
nucleus, mitochondria, endoplasmic reticulum (ER), Golgi complex, digestive vacuoles, and 
contractile vacuoles (for osmoregulation), which are enclosed by a thin plasma membrane [4]. The 
cyst stage, besides being round shaped, is enclosed by a distinctive thick wall, which is made mainly 
of cellulose [5,6]. 
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Figure 1. Life cycle of Acanthamoeba spp. (A) Trophozoite form that divides actively via binary fission. 
(B) Cyst form that represents the dormant stage. Under harsh conditions (e.g., food deprivation, 
extremes in pH, temperature and osmolarity) trophozoites transform into dormant cysts. 
Acanthamoeba trophozoites (15–45 μm) are metabolically and reproductively active in the 
presence of appropriate environmental conditions, such as sufficient nutrients and favorable 
osmolarity, pH and temperature. However, this organism has a remarkable ability to transform into 
a dormant cyst stage (10–25 μm) under stressful conditions, such as adverse temperature, high 
osmolarity, high salination, extreme pH and scarcity of nutrients or drought [7]. Acanthamoeba cysts 
have the ability to persist in the environment for many years without losing their virulence and they 
can be airborne. During this encystation process, Acanthamoeba surrounds itself with a unique capsule 
that consists of two dense layers (inner endocyst and outer ectocyst). A recent study showed that cyst 
wall proteins are largely composed of three groups of cellulose binding lectins and that cyst wall 
formation is a well-orchestrated process whereby lectins bind with glycopolymers to form a well-
developed cyst wall supported with an endocyst layer [8]. This protective cyst wall is what makes 
Acanthamoeba cysts tolerant to antibiotics and biocides including chlorination [7], and can survive 
under extreme physiological, radiological and chemical conditions. Once conditions become 
favorable, cysts switch back to their trophozoite form, a process known as excystation. Cysts are 
primarily responsible for prolonged treatment of Acanthamoeba infections. The majority of available 
drugs target functional aspects such as synthesis of DNA, RNA, protein, cell wall, or metabolic 
activity of the pathogen. However, cysts are dormant and exhibit little, if any, of the aforementioned 
functions, making them resilient to the available drugs. Discovering new anti-acanthamoebic drugs 
capable of tackling the cystic stage is increasingly difficult partly because the cyst wall is impervious 
to most drugs and partly because Acanthamoeba encysts deep within the corneal stroma [2]. These 
properties make cysts hard to target effectively.   
Given the opportunity and host susceptibility, pathogenic Acanthamoeba is notoriously known 
to inflict significant damage on the eye and Central Nervous System (CNS) of the affected 
individuals. Ocular infection by Acanthamoeba is associated with a painful condition, known as 
Acanthamoeba keratitis (AK), with potentially sight threatening consequences. The higher cyst density 
and the presence of a deep corneal ring infiltrate are associated with more severity of AK [9,10]. AK 
is particularly common in people who wear contact lenses [11]. However, non-contact lens users can 
be also affected [12]. Acanthamoeba can cause a fatal encephalitis, but this form of infection is relatively 
underrecognized, probably due to its low prevalence and non-specific clinical symptoms. 
In this review, we summarize the clinical manifestations of Acanthamoeba infection and review 
the current therapeutic strategies along with the challenges for achieving satisfactory treatment 
outcomes. In addition, we highlight the key achievements made in the field of anti-acanthamoebic 
drug discovery, which are expected in the long term to shape the future landscape of treatment of 
Acanthamoeba infection. 
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2. Clinical Features 
The opportunistic protozoa Acanthamoeba castellanii and A. polyphaga can cause severe eye 
infection, leading to the devastating AK condition. Other Acanthamoeba spp., such as A. rhysodes, A. 
culbertsoni, A. hatchetti, A. griffini, A. mauritaniensis, A. lugdunensis of the T4 genotype, and also 
genotypes T1, T2, T3, T5, T6, and T11, have been involved in eye infections. Since the early 1970s, this 
condition has received significant attention from the medical community and the general public in 
part due to increasing use of contact lenses [13]. Amoebic keratitis can represent a challenge to 
ophthalmologists because it is often misdiagnosed with bacterial [14] or fungal [15] infection, given 
the non-specificity of symptoms, particularly during early infection. Any delay in instigating 
appropriate treatment will cause AK to progress from non-specific symptoms to sight-threatening 
consequences, with very poor prognosis. Clinical features of AK include blurred vision, eyelid ptosis, 
agonizing eye pain, photosensitivity, redness of the eye, scleritis, tearing, corneal ulcer, and ring-
shaped infiltrates, especially in late stage or in coinfections [2,16]. Complications associated with AK 
include glaucoma, iris atrophy, anterior synechiae, and cataract.  
Acanthamoeba spp., mostly of the T4 genotype, however T1, T10, T12, have been implicated as 
serious agents of a rare, but invasive brain infection, which is known as granulomatous amebic 
encephalitis (GAE). This condition often occurs in immunocompromised and debilitated patients 
with disturbances in the immune system that render them highly susceptible to GAE, such as those 
with malignancies, AIDS, diabetes, and organ transplant recipients [17–19]. Although pathogenesis 
of GAE is multifaceted and remains largely unknown, the parasite seems to enter the human body 
via the pulmonary route, and through alveolar blood vessel and hematogenous spread it gains access 
to the blood–brain barrier (BBB). Early clinical symptoms include headache, nausea, irritability, 
dizziness and pyrexia, which can overlap with the symptoms associated with viral or bacterial 
meningitis. As the condition progresses, patients may develop abnormal speech, ataxia, confusion, 
flaccid paralysis, hallucination, seizures, stiff neck, and unconsciousness [5,18–20]. The mortality rate 
can exceed 90% [21], when the parasites invade and damage the CNS [21] and cause increased 
intracranial pressure [20]. Severe necrotic brain lesions, including hemorrhaging and edema, can be 
observed via neuroimaging techniques or on post-mortem examination. 
3. Current Anti-Acanthamoebic Therapy 
Anti-acanthamoebic drug therapy is the cornerstone of medical management for Acanthamoeba 
infection, which often involves the use of combination strategies to provide synergistic effects and 
improved treatment outcomes. The treatment regimen normally involves using 0.02% biguanides 
and 0.1% diamidines [22,23]. Biguanides (Polyhexamethylene (PHMB) or chlorhexidine gluconate 
(CHX)) represent the first-line therapeutic option and have proven efficacy in curing patients with 
AK [24]. Biguanides target the plasma membrane of the amoeba leading to membrane damage, lysis, 
and death. The antiseptic diamidines (propamidine isethionate and hexamidine) are active against 
the trophozoites and cysts and exert their effects by disrupting the biosynthesis of protein and nucleic 
acids [25]. An earlier study discouraged the use of propamidine, owing to potential neurotoxicity and 
resistance of the cysts to the drug [26]. Therefore, combination treatment regimens involving 
antiseptic agents have been advocated, however, the evidence for the superiority of the combination 
treatment over monotherapy remains inconclusive [11]. In fact, treatment of AK using 0.02% PHMB 
had similar efficacy to combined biguanide and diamidine therapy [27]. Effective treatment of AK 
requires early diagnosis and timely implementation of a strict treatment regimen in order to achieve 
sufficient eradication of the susceptible trophozoites before they form cysts, which are very difficult 
to eliminate. The treatment regimen starts with hourly administration of eye drops during the first 
two days, followed by hourly eye drops per daytime only for the following five days [28]. Given the 
challenges associated with the management of Acanthamoeba infection, significant efforts have been 
made to develop and test several drugs against Acanthamoeba, such as antiseptics, antibiotics and 
antifungal drugs affecting various targets/functions in Acanthamoeba (Figure 2).  
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Figure 2. Potential targets used in the development of anti-acanthamoebic agents. 
The antiseptics acriflavine and proflavine have activities against trophozoites and cysts, and 
exert their actions by binding to the nuclear and cellular membranes, and compromising the lipid 
bilayer and membrane integrity [25]. Phospholipid analogues have been shown to have trophicidal 
and limited cysticidal activities [29]. They exert their effects by suppressing phospholipid 
biosynthesis, disruption of cellular membranes and intracellular signalling, and induction of 
apoptosis [30]. The herbicide 2,6-dichlorobenzonitrile inhibits cellulose synthesis and encystment of 
the amoeba [31]. The disinfectant povidone-iodine (PVP-I) has both trophicidal and cysticidal effects 
in vitro [32]. It works by damaging protein and nucleic acid synthesis [33]. In vitro study showed that 
at 0.5–2.5% PVP-I has a better activity on the trophozoite and cystic stages than CHX [31]. In vitro 
screening of derivatives of the heterocyclic compounds 1H-benzimidazole and 1H-benzotriazole, and 
their N-alkylated analogues against A. castellanii identified 5,6-dimethyl-1H-benzotriazole and 5,6-
dibromo-1H-benzotriazole to be more cysticidal compared to CHX [34]. Also, the antimetabolite, 
anticancer drugs methotrexate (MTX) and 5-fluorouracil (5-FU) have been shown to inhibit the 
growth of A. castellanii [35]. 
The antibiotics polymyxin B and polymyxin E (known as colistin) target the plasma membrane 
of the target organisms, and possess trophicidal and cysticidal activity in vitro [25]. Limitations 
associated with polymyxins include, nephrotoxicity against human cells, varying efficacies between 
Acanthamoeba spp. and strains, the need to use high concentrations to achieve cysticidal effect [25,36]. 
The aminoglycoside antibiotics (e.g., paromomycin, neomycin, neosporin) exert their effects by 
inhibition of protein synthesis [25]. These compounds have efficacy against both cysts and 
trophozoites in vitro [37,38]. The paromomycin and neomycin are more cysticidal when used together 
with cryotherapy [37,38]. The macrolide antibiotics (e.g., rokitamycin and spiramycin) perform their 
actions by inhibiting protein translation [25]. Rokitamycin had trophistatic activity, and trophicidal 
and cysticidal effects at higher concentrations in vitro [39]. Spiramycin has shown a cysticidal activity, 
but at a high concentration [38]. The folate synthesis inhibitors (e.g., sulphonamides) are trophistatic  
and exert their effects via disruption of the synthesis of folate, which is needed for DNA synthesis 
and cell replication [25]. The anti-infective compound myristamidopropyl dimethylamine (MAPD) 
has shown cysticidal effect in vitro [40].   
The polyene antifungal amphotericin B exerts its effect by binding to sterol ergosterol present in 
the membrane of the fungal cell, and creating pores which result in deploralization and cell leakage 
[25]. Amphotericin B has shown modest efficacy against trophozoite and cystic stages in vitro [38]. 
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The echinocandin antifungal caspofungin has shown strong activity against the cysts and to some 
extent, against trophozoites in vitro [41]. Caspofungin exerts its action by inhibiting β1,3-glucan 
synthase enzyme, leading to inhibition of the synthesis of β1,3-glucan, which represents a key 
constituent in the inner wall of Acanthamoeba cysts [25]. Topical application at low concentrations did 
not cause any adverse effects in rabbits, but toxicity was observed in human cells at 50 μM 
concentration [41]. The azole antifungals (e.g., clotrimazole, fluconazole, ketoconazole, miconazole) 
exert their activities by suppressing ergosterol synthesis in the membrane. Specifically they interfere 
with sterol synthesis via inhibition of CYP-dependent C-14α demethylase enzyme, which plays a role 
in converting lanosterol to ergosterol [42]. These azoles possess limited trophicidal and cysticidal 
activity in vitro [25]. Oral fluconazole has been used for AK treatment, and is probably effective 
following corneal cryosurgery in invasive keratitis [43]. Systemic ketoconazole seems very effective 
for treatment of AK [44] and recurrent infections could be controlled by clotrimazole following 
penetrating keratoplasty [45].  
To our knowledge, a large number of FDA-approved drugs are available. Examples of such 
drugs include pyrimethamine, rifampin, 5-flucytosine, co-trimoxazole, sulfadiazine, pentamidine, 
ketoconazole, fluconazole, itraconazole, azithromycin, amphotericin B, and paromomycin. However, 
no consensus exists on standard therapeutic management of patients with GAE, and clinical cases 
reporting successful treatment outcomes remain scarce. The repurposed anticancer and anti-
leishmaniasis drug miltefosine can significantly eradicate A. castellanii trophozoites at 62.5 μM after 
24 h exposure, however higher concentrations 250 and 500 μM were required to achieve the minimal 
trophocidal concentration for Acanthamoeba spp. and A. lugdunensis, respectively [46]. A previous 
study suggested the added value of combining miltefosine with albendazole and fluconazole for 
treating patients with Balamuthia GAE [47]. Additionally, oral voriconazole and miltefosine reduced 
serological titers and brain lesions in an immunocompetent patient with GAE [48]. These therapeutic 
advantages make miltefosine a good candidate for inclusion in a combination therapeutic regimen 
for management of GAE. 
4. Therapeutic Challenges and Increasing Demands for Better Anti-Acanthamoebic Drugs 
Despite the advances in anti-acanthamoebic therapy and the limited available armamentarium 
of chemotherapeutic agents, management of patients with AK and particularly GAE remains a 
challenge for health services. Unfortunately, there are many limitations with the current therapeutic 
medications. Even with combined treatment, outcomes seem to be promising only in the early-
presenting cases. Also, most of the topical drugs used for treatment of AK are delivered over 
extended period of time [49]. The extended treatment duration is inconvenient for patients who 
continue receiving treatment even after clinical resolution to prevent relapses [2]. Indeed, the 
requirement of a prolonged treatment course to treat AK has been a central dogma in the 
management of Acanthamoeba infection. In addition, current therapeutics can cause toxic keratopathy 
[50] and trigger encystation and formation of resistant amoebic cysts [51]. Furthermore, new evidence 
suggest that microbial coinfections should be suspected in AK cases, which are unresponsive to anti-
acanthamoebic therapy [15]. The increasing frequency of coinfections complicate regimens further 
and require additional therapeutic interventions. 
Any delay in diagnosis can cause treatment challenging because it postpones the initiation of 
timely therapy, which gives sufficient time for the parasite to infiltrate deeper into the corneal tissue, 
potentially encysting to form fully matured cysts, and becoming less responsive to drug treatment(s) 
[52] or even form fully developed cysts [11]. Incorrect diagnosis is more likely to occur during the 
late or advanced phase, where the corneal ulcer of AK often exhibits similar features to keratitis of 
other etiologies [53], specifically fungal keratitis [54] or herpetic keratitis [55]. Treatment outcomes 
can be compromised by various factors, such as age, severity of illness, treatment with corticosteroids 
before the diagnosis of AK, or coinfections. Patients with high AK disease severity at diagnosis that 
previously used corticosteroids prior to diagnosis are more likely to have a less successful treatment 
outcome [56]. The correlation between the in vivo confocal microscopy-morphological features 
(IVCM-MF) for determining Acanthamoeba cyst density (ACD) and clinical staging of AK on 
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presentation suggests that IVCM-MF can be used to predict the visual outcome in patients with AK 
[10]. 
Controversies surround the inclusion of corticosteroids in the treatment plans for AK arise from 
the lack of a conclusive evidence and from conflicting findings between different studies. On one 
hand, a link between using steroid eye drops and keratic precipitates during severe Acanthamoeba 
infection has been suggested [57]. Also, steroid treatment has been shown to exacerbate AK in rabbit 
corneas [58]. On the other hand, treatment regimen for AK that includes corticosteroids has been 
proposed as a means to reduce the pain and discomfort, limit corneal vascularization [59] and reduce 
corneal inflammation [60]. Another study showed that adding topical corticosteroid after initiation 
of anti-acanthamoebic therapy does not seem to worsen the clinical outcomes of AK [61]. Therefore, 
the beneficial benefits of corticosteroids should be balanced against their potential side effects. Also, 
patients should continue to receive anti-acanthamoebic therapy after topical corticosteroids are 
discontinued to avoid relapses [11]. When conservative treatment fails, non-pharmacological surgical 
interventions, such as amniotic membrane grafts, cryotherapy of the cornea, riboflavin/UVA corneal 
crosslinking, and keratoplasty can be of value in the management of AK, as a last resort [50]. 
Unfortunately, despite intensive medical and surgical treatment some advanced AK cases with 
persistent or recurrent infection may require enucleation of the eye [62]. 
Biguanide drugs require a prolonged treatment course that can last for several months [63]. 
Prolonged treatment regimens can induce adverse effects given the cytotoxicity of topical biguanides 
[64,65]. In fact, ocular health complications associated with progressive AK have been ascribed to 
cytotoxicity following lengthy topical administration of biguanides and/or chlorhexidine gluconate 
[11,66,67]. New combination therapeutic regimens are required that can improve treatment efficacy, 
without exacerbating adverse reactions. One major challenge in finding safer therapeutic substances 
is the similarity between the eukaryote Acanthamoeba and the mammalian host [68]. Discovery of new 
effective drugs would require identification of compounds that are more selective to Acanthamoeba-
specific cellular components than to the mammalian cells. Further efforts to identify short-course 
therapeutic regimens that are highly effective in eradicating Acanthamoeba from the affected eye, with 
the very minimal side effects possible and with the least number of drugs, would be useful not only 
to improve patient outcome and reduce adverse reactions, but also to reduce the complexity of 
treatment regimens and enhance the compliance of patients to medication.  
Treatment of patients with GAE is even more challenging than treatment of patients with AK.  
The mortality rate estimates associated with GAE can be too high [18,19,21] and treatment has been 
hampered by the scarcity of a reliable drug delivery method and the inability of current drugs to 
overcome the BBB and penetrate into brain parenchyma in sufficient concentrations to kill the 
amoeba. Despite the report of many chemical compounds that can block or reduce the growth of the 
Acanthamoeba in vitro, as discussed in the subsequent sections, only a few are likely to realize their 
full therapeutic potential in the clinical setting. 
5. Anti-Acanthamoeba Drug Discovery 
5.1. Repurposed Drugs 
Recent studies have shown that existing drugs used clinically for other diseases may have the 
potential to target Acanthamoeba infections. With anti-acanthamoebic effects, they can progress to 
randomized, controlled clinical trials to evaluate their effectiveness against Acanthamoeba infections, 
which would save time and drug development costs. For example, three FDA-approved marketed 
drugs, amlodipine, loperamide, and prochlorperazine were shown to exhibit potent trophicidal 
effects [69]. Amlodipine is a dihydropyridine calcium channel blocker used in the treatment of 
hypertension and angina pectoris. Loperamide is a widely used antidiarrheal drug that acts primarily 
through activation of opioid receptors. Prochlorperazine, a drug of the same class as trifluoperazine, 
exhibited potent amoebicidal effects. Haloperidol and prochlorperazine act primarily as dopamine 
receptor blockers and have been used as anti-psychotic drugs. It was interesting to note that 
prochlorperazine showed potent trophicidal as well as cysticidal effects, while haloperidol was 
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effective against trophozoites but not cysts. A combination of chlorpromazine and rokitamycin 
exhibited synergistic trophistatic , trophicidal, and cysticidal activities against A. castellanii suggesting 
their usefulness as chemotherapeutic agents against Acanthamoeba infections. The precise mode of 
action of prochlorperazine against Acanthamoeba is unclear but it may involve inhibition of amoeba 
calcium regulatory proteins, or lipophilic action on the amoeba plasma membrane. Prochlorperazine 
is thought to exert its anti-psychotic effects by blocking dopamine receptors but also has moderate 
anti-cholinergic and alpha-adrenergic receptor-blocking activity, as compared to haloperidol, which 
is a weak anti-cholinergic, muscarinic M1 (silent antagonist) at 10 μM [70]. Another anti-cholinergic 
agent, procyclidine, which is widely used as anti-parkinsonian agents because of its anti-cholinergic 
action showed trophicidal effects. Digoxin is a potent inhibitor of the active transport of sodium and 
potassium across cell membranes and showed trophicidal effects, possibly through a combination of 
lytic and apoptotic signaling induction. As there is limited availability of effective drugs to treat 
Acanthamoeba infections, clinically available drugs offer potential agents in managing AK and GAE. 
Repurposing drugs suggests the presence of a pharmacophore with microbicidal activity [71] 
providing an incentive for further investigation into compounds with similar structures. Exploring 
novel indications for existing drugs is an attractive short-term strategy offering major savings in 
development time and expense. Similarly, corifungin (a water-soluble polyene macrolide) and 
tigecycline (a third-generation tetracycline) were found to reduce Acanthamoeba growth (73% and 46% 
inhibition at 100 μM, respectively) by degenerating cytoplasm architecture and dysfunctioning the 
mitochondria of A. castellanii trophozoites [72–74]. Drugs that target G-protein coupled receptors 
(GPCRs) i.e., dopamine, muscarinic receptors, α- or β-adrenergic receptors and 5HT receptors have 
also been used due to their critical role in cellular signaling. Inhibition of β adrenergic receptor by 
propranolol affected A. castellanii growth, encystation and viability [75]. Combinations of 
prochlorperazine plus loperamide, prochlorperazine plus apomorphine and procyclidine plus 
loperamide were proved to be amoebicidal against A. castellanii [21]. Moreover, chloroquine, an anti-
malarial drug, was able to inhibit autophagy, a type of programmed cell death (PCD), which was 
highly stimulated during encystation of Acanthamoeba, leading to reduction in the survival of A. 
castellanii [73]. Atorvastatin, fluvastatin, simvastatin and voriconazole could also induce PCD in A. 
castellanii [76]. 
5.2. Improvements in Existing Drugs 
The reformulation or analogues of drugs can improve compliance, pharmacodynamics and 
pharmacokinetics, making current medicines more clinically effective. High throughput screening of 
structural analogues of miltefosine such as heterocyclic alkylphosphocholines (APCs) [77] and 
oleylphosphocholine (OlPC) [78] demonstrated similar or stronger in vivo efficacy compared to 
miltefosine. It is worth noting that heterocyclic alkylphosphocholines possess ability to cross the BBB 
[79] and have potential in treating GAE due to Acanthamoeba and possibly other brain-infecting 
amoebae. Recently several studies have shown that the efficacy of marketed drugs can be enhanced 
by conjugation with metals such as gold or silver to synthesize drug-conjugated metal nanoparticles 
and can be repurposed as potential drugs for treating infections due to pathogenic free-living 
amoebae [80]. However, the use of metal nanoparticles can be associated with cytotoxicity [81] and 
side effects [82].  
To develop a holistic approach to control AK certain measures should be included to augment 
pharmacotherapy, for example, by reducing incidence of eye infection by including new compounds 
with proven efficacies against trophozoites and cysts in cleaning solutions of contact lenses. In this 
regard, a recent study [83] showed that quaternary ammonium compounds (QACs) are more potent 
than APCs and had cysticidal activity against matured cysts at IC50s 19.00  ±  0.03  μg/mL and 15.00  ± 
0.06  μg/mL for QAC16, and QAC18, respectively. QAC with 12 alkyl carbon chain (QAC12) 
increased the biomass of trophozoites, delayed encystation by 96 h, but failed to trigger excystation. 
However, QAC12 potentiated the toxicity of APC16 against trophozoites. The toxicity of QACs was 
related to the length of the alkyl-carbon chain and was achieved by producing permeabilization and 
DNA complexing in trophozoites. The effects of combining atorvastatin (a statin used to lower blood 
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cholesterol) with two eye drops (Optiben and Diclofenaco-lepori (D-L)) against A. castellanii and on 
the viability of a murine macrophage were investigated. The ideal combination that reduced the 
parasite growth without causing cytotoxicity was 30% Optiben, 63.5% atorvastatin, and 3.1% water. 
In addition, the most effective combination that inhibited the parasite growth with limited 
cytotoxicity was 17.6% Diclofenaco-lepori and 82.4% atorvastatin [84]. Another study reported low 
EC50 values for prodigiosin (2.2 μM) and obatoclax (0.5 μM) against A. castellanii trophozoites [85]. 
5.3. siRNA-Based Therapeutics 
Small interfering RNA molecules (siRNAs) have highlighted the benefits of existing statins 
against AK [86]. siRNA molecules can be synthesized artificially to silence or knockdown a particular 
mRNA. They could be used as a potent therapeutic option or a method for target validation in drug 
discovery. Specific targets investigated include extracellular serine protease [87], xylose isomerase 
[88], encystation-mediating serine proteinase (EMSP) [89], protein kinase C [90], cellulose synthase 
[91], protein arginine methyltransferase 1 [92], cysteine protease inhibitor (AcStefin) [93], and 3-
Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) [86]. It was found that after silencing the 
aforementioned targets by siRNA, encystation was prevented. It was also proposed that a 
combination of two gene-specific siRNAs (one targeting serine proteases and one targeting glycogen 
phosphorylase) could affect the growth rate and survival of amoeba [94]. Later, Zorzi et al. [95] 
designed siRNA-loaded liposomes for the successful treatment of a murine model of ocular keratitis 
caused by Acanthamoeba, further highlighting siRNAs as a promising future therapeutic approach.  
5.4. Alternative Therapeutics 
The effectiveness of a murine monoclonal anti-idiotypic antibody and a synthetic killer 
mimotope (resembling a yeast toxin) in inhibiting and damaging Acanthamoeba growth on contact 
lenses has been shown [96]. Therefore, these biologics show clinical potential for development in 
order to prevent Acanthamoeba growth on contact lenses. These would consist of an A. castellanii-
specific Fab portion that is specific for its surface, covalently linked to the A chain of the diphtheria 
toxin [97]. Similarly, photodynamic chemotherapy is a novel intervention that involves the use of 
Acanthamoeba-specific antibodies linked to photosensitizers like phthalocyanine (RLP068) or 
Hypocrellin B [53]. Photodynamic therapy may be advantageous over conventional methods. It is a 
treatment that involves the use of light-sensitive medication and a light source to destroy cells. 
Incubation of cysts with compounds and irradiation with 600–700nm light has been found to cause 
rapid and extensive damage, but its clinical validity is yet to be confirmed [98]. 
Photochemotherapeutic strategy was proposed to target Acanthamoeba infections. As mannose-
binding protein is expressed on the surface membranes, photosensitizing compound porphyrin 
conjugated with mannose could achieve more specific drug targeting. Pre-treatment with this could 
reduce host cell cytotoxicity from 97% to 4.9% [99]. A recent study showed that Rose bengal 
photodynamic antimicrobial therapy can reduce parasitic load and diminished clinical severity of AK 
in a rabbit model [100]. 
5.5. Natural Compounds 
Traditionally many drugs with biological activity were discovered from natural compounds. 
Among a plethora of natural compounds tested, a few examples include Ipomoea spp., Kaempferia 
galanga, Cananga odorata [101], oakmoss (a natural fragrance ingredient) [102], a hexane fraction of 
Pterocaulon polystachyum (Asteraceae) [103], ethyl acetate extract of Limouni olive leaf [104], 
resveratrol and curcuminoids [105] were found to be amoebicidal. Of note, resveratrol is of high 
interest for further investigation because it can prevent amoeba binding to the human brain 
microvascular endothelial cells (hBMECs) and it is selective to A. castellanii, but not the hBMECs [105]. 
Interestingly, resveratrol could also act as a topoisomerase II inhibitor [106] that prevents DNA 
ligation and subsequently leads to cell apoptosis. Plant extracts from Rubus chamaemorus, Pueraria 
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lobate and Solidago virgaurea could also be used in combination with other GAE drugs as they were 
found to extend the survival of Acanthamoeba-infected animals [107].  
Plant-derived artemisinin and artesunate have caused 93% reduction in the trophozoite growth 
[108]. They exert their amoebistatic activity via induction of reactive oxygen species and lipid 
peroxidation, leading to oxidative stress and apoptosis [25]. Magainins, peptides produced by the 
skin of the African frog, had both trophistatic and trophicidal activities in vitro. Their anti-
acanthamoebic effects are attributed to interruption of the ion conductance across the cell membrane 
[109]. A recent study showed that a number of natural compounds of plant or commercial origins 
(e.g., quercetin, kolavenic acid extracted from plant Polyalthia longifolia var pendula and crude plant 
methanolic extract of Caesalpinia pulcherrima) exhibited considerable suppression of the amoebae 
growth [110]. Conjugation of the plant-derived compounds (e.g., quercetin) with silver nanoparticles 
increased their anti-acanthamoebic effect, and reduced the encystation and excystation of A. 
castellanii, without exhibiting toxicity against human cells [110]. Taken collectively, this broad range 
of nutraceuticals display promising anti-acanthamoebic potential, making natural products 
interesting drug leads in the foreseeable future.   
5.6. Potential Targets for New Anti-Acanthamoeba Therapy 
Many pharmacological targets have been discovered over the last few years [30]. For example, 
the myosin superfamily includes 18 different classes of motor proteins. Of the many classes that are 
expressed in Acanthamoeba, myosin-I and -II have been studied most extensively. The function of both 
myosins is based on the use of ATP hydrolysis to generate forces required for cellular functions. 
Acanthamoeba expresses three types of myosin-I subtypes, myosin-IA, -IB, and -IC. Myosin-IA 
functions in cytoplasmic vesicle transport, myosin-IB functions in pseudopod extension and 
phagocytosis, and myosin-IC is the only subtype that functions in contractile vacuole [25]. 
Acanthamoeba myosin-IC was of particular interest as it performs functions that human myosin-IC 
lacks and it is only 44% homologous to human myosin-IC [111]. The contractile vacuole is highly 
important in Acanthamoeba because it maintains homeostasis by regulating the amount of water 
within amoeba. It absorbs water by osmosis from the cytoplasm and moves to the surface of the 
amoeba and undergoes exocytosis when full. If myosin-IC is blocked, Acanthamoeba would be unable 
to regulate its internal water content and ultimately lead to cell lysis. Pentachloropseudilin (PCIP), a 
non-competitive, reversible myosin-IC inhibitor, is the only specific myosin-IC inhibitor developed 
and tested on Hela cells [112] but has not been tested on Acanthamoeba. It works by reducing the 
coupling between actin and nucleotide blinding sites [111]. Looking at the effects of PCIP analogues 
to inhibit or kill trophozoites might provide additional insight to current therapy.  
Moxifloxacin has shown limited efficacy against Acanthamoeba and exerts its effect by inhibition 
of DNA gyrase, a type II topoisomerase, and topoisomerase IV, which is required for DNA 
replication. Topoisomerase I inhibitors (e.g., camptothecin, irinotecan, topotecan) and topoisomerase 
II inhibitors (e.g., doxorubicin, amsacrine, etoposide) are generally used as anti-cancer drugs to 
induce apoptosis and death of cancer cells, and may have a potential activity against Acanthamoeba. 
High levels of elastase activity were found in A. culbertsoni [18]. Hence, it will be important to examine 
the potential of elastase inhibitors to inhibit Acanthamoeba elaborate elastase, a type of protease that 
degrades connective tissue proteins and causes cellular damage. The majority of the cyst wall 
structure is cellulose; thus, targeting cellulose biosynthesis can prevent encystment. The 2,6-
dichlorobenzonitrile (DCB), a cellulose synthesis inhibitor, blocked Acanthamoeba encystment [113]. 
Using cellulase to the degrade cyst wall might make amoeba more susceptible to therapeutic 
compounds [114]. Alkaline phosphates have been identified in Acanthamoeba contractile vacuoles 
[115] and can be targeted by compounds, such as polyoxometalates. A. castellanii was found to have 
a novel complement of shikimate pathway enzymes [116]. Using (6S)-6-fluoroshikimic acid 
(antibacterial) and glyphosate (herbicide) can be a new approach to inhibit the shikimate pathway 
enzymes. 
Agents that affect membrane sterols, which are present in trophozoites and cysts, but absent 
from the host cells, have the potential to selectively suppress the amoeba growth. This assumption 
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motivated Shing et al. [117] to examine the anti-acanthamoebic potential of the FDA-approved 
antifungal conazoles, which target sterol 14-demethylase (CYP51). Isavuconazole and posaconazole 
showed high efficacies against A. castellanii trophozoites. Additionally, isavuconazole damaged 
trophozoites within a day and suppressed excystation. Given the high safety of isavuconazole and 
its ability to block A. castellanii excystation, this drug was suggested as a cost-effective option for the 
treatment of primary and repeated AK. Reyes-Batlle et al., [118] identified new N-substituted 
quinolin-2(1H)-ones compounds with selective toxicity against trophozoites and cysts. The 
compounds’ toxicity was attributed to their ability to significantly lower the levels of ATP, without 
increasing the permeability of the cell membrane, leading to apoptosis and death of the amoeba. The 
promising potential of N-acyl substituted quinolin-2(1H)-ones suggests that these compounds may 
serve as a new scaffold for the identification of novel and better anti-acanthamoebic drugs.  
5.7. New Anti-Acanthamoebic Approaches  
The application of riboflavin (B2) and concurrent ultraviolet light A (UVA) exposure to the 
cornea has shown potential as a new approach for AK therapy. UV irradiation of B2 produces free 
radicals that cause oxidation and cross-linking of the corneal collagen [119,120]. This prevents further 
tissue damage and parasitic reproduction by damaging their nucleic acid material [121]. Despite the 
potential, there has been no confirmation from clinical trials to incorporate this as a mainstay therapy. 
The use of drug-carriers improves the penetration of existing drugs into cystic forms in ocular or 
nasal drug administration. Current drugs; propamidine isethionate 0.1%, neomycin 1% or 
miconazole 1% lack cysticidal activity, however when combined with dimethyl-sulfoxide 30%, 
propamidine isethionate 0.1% exhibited better cysticidal activity. As dimethyl-sulfoxide itself has 
been used topically in the past, it can be considered clinically safe [122]. Furthermore, liposomal 
carriers of pentamidine isethionate improve the drug’s potency in vitro [123] and chitosan 
microspheres have been found to improve rokitamycin’s anti-amoebic activity and dissolution rate, 
providing a controlled-drug release [124]. More recently, drug conjugation with metals such as gold 
or silver to synthesize drug-conjugated metal nanoparticles have shown tremendous potential in the 
improved killing of parasites in vitro [80].  
5.8. Improved Drug Delivery to the Blood–Brain Barrier 
Effective treatment depends heavily on the drug’s ability to cross the BBB as drug transport is 
often hampered by highly selective BBB. The majority of drugs that target the brain in clinical practice 
are lipid soluble small molecules (i.e., antibiotics) with molecular weight < 400 Da [125]. Among all 
the drugs that were used to treat GAE, none were delivered specifically to the CNS and limited 
research is done to improve their delivery to the BBB. Although a liposomal delivery is an available 
drug delivery option for amphotericin B (Ambisome) to enhance its lipid solubility, it was generally 
unable to cross the BBB [126]. In addition, despite the presence of rifampin and pyrimethamine in 
effective concentrations in the CSF (another gateway of drug transport to the brain), they transport 
poorly to the brain [125]. The development of improved drug delivery methods for current anti-
acanthamoebic drugs is crucial to enhance the action of existing drugs until novel compounds with 
increased potency are available. 
Four main approaches are currently used to deliver drugs to the CNS [25]: i) transcranial drug 
delivery (injection in the cranium), ii) intranasal drug delivery that provide direct drug transport to 
the CSF, iii) transient modification of BBB i.e., increase BBB permeability using ultrasound or 
electromagnetic heating of nanoparticles [127] and iv) modification of physiochemical properties of 
drugs such as the lipidization of small molecules, lipid-based nanotherapeutics for the delivery of 
siRNA, and drug-conjugation with metals such as gold or silver to form drug-conjugated metal 
nanoparticles [128] and microspheres encapsulation to improve and prolong in vitro anti-amoebic 
activity. An example of microsphere was rokitamycin, an anti-acanthamoebic macrolide, loaded in 
microspheres showed better solubility, penetration, and enhancement [124]. 
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5.9. Theranostics as A Potential Strategy  
The theranostic approaches, which combine therapeutic and diagnostic methods in one 
platform, have the potential to overcome conventional diagnostic and therapeutic limitations 
associated with the management of neglected diseases such as Acanthamoeba infections. Recent 
studies have proposed the theranostic strategy against infections due to pathogenic free-living 
amoebae [129]. It is hoped that such development can help expedite timely and sensitive diagnosis 
augmented with effective therapeutic capabilities. However, it requires development of smart 
materials for improved laboratory and point-of-care testing. Nanomaterials have already shown 
promising theranostic applications in non-communicable diseases and these can provide a 
breakthrough against Acanthamoeba infections.  
6. Conclusions 
In recent years, considerable advances have been made in identifying new molecular targets 
with novel mechanisms of action for the treatment of largely neglected Acanthamoeba infections. 
Although concerns remain regarding the lack of drugs with high anti-acanthamoebic efficacy and 
low toxicity, the potential of some existing medicines to be repurposed for anti-acanthamoebic 
indication is being explored to address these issues. In particular, the theranostic approach is 
considered as a highly valuable approach in targeting infections caused by pathogenic amoebae. 
Significant efforts are still needed to employ alternative or adjunct treatment approaches for the 
development and evaluation of more effective and safer therapeutic modalities. In this review, we 
discussed key research areas that can bolster the anti-acanthamoebic drug pipeline and can, in the 
long term, tackle the current unmet clinical needs in the treatment of Acanthamoeba infection.  
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